Other Deal Trends 2026: Activity Surges 2400% in 6 Months

Twenty-four deals in six months — up from zero in the prior period — represent a 2400% surge in deal activity classified outside traditional therapeutic-area boundaries between March 3 and August 31, 2026. Compared to the September 2025–March 2026 window, which registered exactly zero transactions, the acceleration is not a rounding error. It reflects a structural pivot: Big Pharma is buying capabilities, not just molecules, and the traditional TA-centric licensing framework is failing to capture what's actually happening in BD.

The Data — Other Deal Activity, Period over Period

The baseline of zero makes the percentage technically infinite in some calculations, but even treated as a step-function change, 24 deals in a category that was dormant six months ago demands attention. This isn't noise. It's a signal that deal teams across pharma are pursuing assets and partnerships that don't fit neatly into oncology, immunology, or CNS buckets — and that the nature of other licensing 2026 is fundamentally different from anything tracked in 2024 or 2025.

What's Driving the Trend

Three forces converge to explain this surge. First, platform-level M&A has replaced asset-level licensing as the dominant deal architecture for Big Pharma's most strategic bets. The Bio-Techne/Merck KGaA transaction — at $11.3B in total deal value — is not a therapeutic licensing deal. It's an acquisition of enabling technology infrastructure: protein sciences, reagents, diagnostics, and biologics tools that underpin drug discovery across every therapeutic area. When a deal spans the entire pipeline rather than a single program, it falls outside TA classification. Expect more of this as pharma companies race to own the picks and shovels, not just the gold claims.

Second, the AI-native drug discovery wave has created an entirely new deal category. Generate: Biomedicines' partnership with Novartis exemplifies this. Generative biology platforms don't license a compound — they license a method of producing compounds. These deals are structurally different: milestone triggers are often tied to platform validation, not clinical endpoints. Traditional deal benchmarking struggles with these structures, which is why tools like Deal Benchmarks are adding platform-deal comparables. BD teams that rely on historical TA-specific comps for these negotiations are bringing the wrong map.

Third, cross-border diversification deals are accelerating. YaoPharma's $2.05B TDV partnership with Pfizer signals that Western pharma is still aggressively sourcing from China — but increasingly for assets or capabilities (manufacturing, formulation, distribution infrastructure) that resist TA classification. The $150M upfront on the YaoPharma deal suggests Pfizer is paying real money for near-term value, not just optionality. With IRA pricing pressure compressing margins on branded therapeutics, pharma companies are seeking margin through operational capabilities, not just pipeline shots on goal.

Notable Deals

Bio-Techne / Merck KGaA dominates this dataset — appearing multiple times as reporting windows captured different disclosures of the same mega-transaction. At $11.3B, this is one of the largest non-therapeutic acquisitions in biopharma history. Merck KGaA is not buying a drug. It's buying the infrastructure layer that supports biologics development across its entire portfolio and positions it as a supplier to competitors. This is a vertical integration play, reminiscent of Danaher's Cytiva build-out, but executed through a single acquisition. The strategic logic is sound: own the tools, tax the ecosystem.

Generate: Biomedicines / Novartis is the deal to watch for future structure precedent, even without disclosed financials. Novartis has been the most aggressive Big Pharma adopter of AI-native platforms — the Isomorphic Labs deal earlier in 2026 set a template. The absence of disclosed upfront and TDV numbers suggests either a highly option-loaded structure or an equity-based arrangement, both of which are becoming more common in platform deals where value is probabilistic and multi-program.

YaoPharma / Pfizer at $150M upfront and $2.05B TDV is the most conventionally structured deal in this set, but its classification as "other" rather than within a specific TA tells you something about what Pfizer is actually acquiring. The 7.3% upfront-to-TDV ratio sits below the 2026 median of roughly 10-12% for TA-specific deals tracked on Deal Benchmarks, suggesting Pfizer negotiated favorable terms — likely leveraging its distribution infrastructure as the real value-add.

What This Means for BD Teams Right Now

If you're selling a platform asset, this is your market. Twenty-four deals in six months after a dead period means buyers are actively hunting. But the concentration of value in mega-deals (Bio-Techne alone accounts for the vast majority of total deal value in this category) means the median deal is still modest. Don't mistake the Bio-Techne headline for your own valuation floor. If your platform has multi-TA applicability, position it that way — but back the valuation with data on programs enabled, not theoretical addressable market.

If you're buying, move now but structure defensively. The surge from zero to 24 deals suggests a land-grab dynamic. Platform assets that enable drug discovery across therapeutic areas are finite. Once a Merck KGaA takes Bio-Techne off the board, competitors must either build internally (18-24 month delay) or pay a premium for the next-best alternative. Option-heavy structures with platform validation milestones protect against overpayment while securing access.

Deal structures are shifting toward hybrid models. Pure royalty-based licensing makes less sense for platform deals where the asset generates value across dozens of programs. Expect more equity components, cost-sharing arrangements, and milestone structures tied to platform throughput rather than individual candidate progression. BD teams should be modeling these structures now — the Ambrosia calculator can benchmark your proposed terms against current market rates for non-traditional deal architectures.

The other deal trends 2026 data makes one thing clear: the boundaries between therapeutic licensing, technology acquisition, and infrastructure investment are dissolving. BD teams that operate exclusively within TA silos will miss the deals that are actually reshaping competitive positioning. The winners are already working cross-functionally — linking corporate development, technology scouting, and commercial strategy into a single deal thesis.

Benchmark your deal against current market rates. Whether you're structuring a platform partnership or evaluating an acquisition target that defies traditional TA classification, use the Ambrosia calculator to stress-test your terms against the 24 deals that have already closed in this space.